Could a Low-Dose immune drug ease long COVID symptoms?

NCT ID NCT06960928

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a low dose of sirolimus (rapamycin), a drug that calms the immune system, can help adults with Long COVID feel better. Eighty participants will take either sirolimus or a placebo pill once a week for 12 weeks. The main goal is to see if the drug improves self-rated health and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus (rapamycin)
What this could lead to: If it works, this could point toward a treatment that improves overall health and quality of life for people with Long COVID.
What could go wrong: This is a small, early Phase 3 trial with only 80 participants. The drug is being used off-label, and results may not apply to everyone with Long COVID. Side effects of sirolimus are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID-19

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.